Results 211 to 220 of about 125,674 (260)

Correction: Weber et al. Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl⁺ K562 and Jak2(V617F)⁺ HEL Leukemia Cells. <i>Cancers</i> 2015, <i>7</i>, 503-537. [PDF]

Cancers (Basel)
Weber A, Borghouts C, Brendel C, Moriggl R, Delis N, Brill B, Vafaizadeh V, Groner B.   +7 more
europepmc   +1 more source

BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India. [PDF]

Leuk Res Rep
S A, Shah A, Ashish A, Kumar Singh N, Kaur M, Kumar Yadav A, Singh R.   +6 more
europepmc   +1 more source

FL118 Is a Potent Therapeutic Agent against Chronic Myeloid Leukemia Resistant to BCR-ABL Inhibitors through Targeting RNA Helicase DDX5. [PDF]

Int J Mol Sci
Takeda K, Ohta S, Nagao M, Kobayashi E, Tago K, Funakoshi-Tago M.   +5 more
europepmc   +1 more source

Chronic myeloid leukemia with two rare fusion gene transcripts of atypical BCR::ABL: A case report and literature review. [PDF]

Medicine (Baltimore)
Li Y, Zhang Y, Meng X, Chen S, Wang T, Zhang L, Ma X.   +6 more
europepmc   +1 more source

A Retrospective Analysis of BCR-ABL-1 Kinase Domain Mutations in Frontline TKI Resistant Chronic Myeloid Leukemia Patients: A Single Centre Experience. [PDF]

Indian J Hematol Blood Transfus
Datta G, Verma SP, Tripathi AK.
europepmc   +1 more source

Editor's Note to: Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1-BCR-ABL-JAK2 Complex. [PDF]

J Natl Cancer Inst
europepmc   +1 more source

The molecular signature of BCR::ABL^P210 and BCR::ABL^T315I in a Drosophila melanogaster chronic myeloid leukemia model. [PDF]

iScience
Baassiri A, Ghais A, Kurdi A, Rahal E, Nasr R, Shirinian M.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

A Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.

Journal of Medicinal Chemistry, 2020
The BCR-ABL fusion oncoprotein causes CML or some ALL in Ph+ patients because the ABL kinase is constitutively activated. However, current clinical treatment with ABL inhibitors is seriously limited by the drug resistance and adverse effects.
Yiqing Yang, Hongying Gao, Xiuyun Sun, Yonghui Sun, Yue-ping Qiu, Qinjie Weng, Yu Rao   +6 more
semanticscholar   +1 more source

Recent advances in Bcr‐Abl tyrosine kinase inhibitors for overriding T315I mutation

Chemical Biology and Drug Design, 2020
BCR‐ABL is a gene produced by the fusion of the bcr gene and the c‐abl proto‐oncogene and is considered to be the main cause of chronic myelogenous leukemia (CML) production.
Juan Liu, Yuan Zhang, Honglin Huang, X. Lei, Guotao Tang, Xuan Cao, Junmei Peng   +6 more
semanticscholar   +1 more source